TG Therapeutics, Inc. (NASDAQ:TGTX) Given Consensus Recommendation of “Moderate Buy” by Analysts

TG Therapeutics, Inc. (NASDAQ:TGTX) has earned a consensus recommendation of “Moderate Buy” from the six analysts that are covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation, three have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $50.75.

Several research analysts have recently weighed in on the stock. HC Wainwright assumed coverage on shares of TG Therapeutics in a research note on Monday, October 6th. They set a “buy” rating and a $60.00 price target on the stock. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of TG Therapeutics in a report on Monday, December 29th. JPMorgan Chase & Co. boosted their price target on TG Therapeutics from $46.00 to $49.00 and gave the company an “overweight” rating in a report on Monday, November 3rd. Wall Street Zen upgraded TG Therapeutics from a “hold” rating to a “buy” rating in a research report on Sunday, December 14th. Finally, The Goldman Sachs Group lifted their price objective on TG Therapeutics from $37.00 to $39.00 and gave the company a “neutral” rating in a research report on Thursday, January 15th.

TG Therapeutics Trading Down 1.4%

TG Therapeutics stock opened at $31.20 on Tuesday. TG Therapeutics has a 52-week low of $25.28 and a 52-week high of $46.48. The company has a market cap of $4.95 billion, a P/E ratio of 11.22 and a beta of 1.86. The company has a quick ratio of 2.89, a current ratio of 3.82 and a debt-to-equity ratio of 0.40. The business has a 50-day simple moving average of $30.80 and a two-hundred day simple moving average of $32.32.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Monday, November 3rd. The biopharmaceutical company reported $2.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.24 by $2.19. The company had revenue of $161.71 million for the quarter, compared to the consensus estimate of $152.12 million. TG Therapeutics had a net margin of 84.13% and a return on equity of 133.24%. The firm’s revenue was up 92.7% compared to the same quarter last year. During the same quarter last year, the firm posted $0.02 earnings per share. Analysts predict that TG Therapeutics will post 0.08 EPS for the current year.

Insiders Place Their Bets

In other news, Director Yann Echelard sold 5,000 shares of the company’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $32.57, for a total value of $162,850.00. Following the completion of the transaction, the director owned 223,816 shares of the company’s stock, valued at $7,289,687.12. This represents a 2.19% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 10.64% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in TGTX. Royal Bank of Canada lifted its holdings in shares of TG Therapeutics by 16.4% in the 1st quarter. Royal Bank of Canada now owns 75,692 shares of the biopharmaceutical company’s stock valued at $2,985,000 after acquiring an additional 10,660 shares during the last quarter. NewEdge Advisors LLC increased its stake in TG Therapeutics by 9.6% during the first quarter. NewEdge Advisors LLC now owns 7,593 shares of the biopharmaceutical company’s stock worth $299,000 after acquiring an additional 665 shares during the last quarter. Goldman Sachs Group Inc. raised its position in TG Therapeutics by 21.9% during the first quarter. Goldman Sachs Group Inc. now owns 1,919,416 shares of the biopharmaceutical company’s stock valued at $75,683,000 after purchasing an additional 345,059 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of TG Therapeutics by 5.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 287,059 shares of the biopharmaceutical company’s stock valued at $11,319,000 after purchasing an additional 14,689 shares during the last quarter. Finally, State of Alaska Department of Revenue lifted its stake in shares of TG Therapeutics by 9.2% in the 2nd quarter. State of Alaska Department of Revenue now owns 80,783 shares of the biopharmaceutical company’s stock valued at $2,906,000 after purchasing an additional 6,827 shares during the last quarter. 58.58% of the stock is owned by hedge funds and other institutional investors.

About TG Therapeutics

TG Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in New York City that specializes in developing targeted therapies for hematological malignancies and autoimmune diseases. The company’s research strategy focuses on the modulation of B-cell biology through novel antibody and small‐molecule agents. Since its founding in 2003, TG Therapeutics has built a diversified portfolio aimed at addressing unmet medical needs in oncology and immunology.

In December 2022, TG Therapeutics achieved its first commercial milestone when ublituximab-xiiy (marketed as Briumvi® in collaboration with Biogen) received U.S.